References
- Atlas of MS 2013: Mapping multiple sclerosis around the worldMultiple Sclerosis International FederationLondon, UK Available from: http://www.msif.org/about-us/advocacy/atlas/Accessed December 23, 2015
- KisterIBaconTEChamotENatural history of multiple sclerosis symptomsInt J MS Care201315314615824453777
- RizzoMAHadjimichaelOCPreiningerovaJVollmerTLPrevalence and treatment of spasticity reported by multiple sclerosis patientsMult Scler200410558959515471378
- PotterDJA review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UKDrug Test Anal201461–2313824115748
- WadeDTMakelaPRobsonPHouseHBatemanCDo cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patientsMult Scler200410443444115327042
- CollinCDaviesPMutibokoIKRatcliffeSSativex Spasticity in MS Study GroupRandomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosisEur J Neurol200714329029617355549
- CollinCEhlerEWaberzinekGA double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosisNeurol Res201032545145920307378
- NovotnaAMaresJRatcliffeSA randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisEur J Neurol20111891122113121362108
- VachováMNovotnáAMaresJA multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosisJ Mult Scler20141210000122
- SerpellMGNotcuttWCollinCSativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosisJ Neurol2013260128529522878432
- WadeDTMakelaPMHouseHBatemanCRobsonPLong-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosisMult Scler200612563964517086911
- AllsopDJNorbergMMCopelandJFuSBudneyAJThe Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distressDrug Alcohol Depend20111191–212312921724338
- AllsopDJCopelandJNorbergMMQuantifying the clinical significance of cannabis withdrawalPLoS One201279e4486423049760
- KoehlerJFenebergWMeierMPöllmannWClinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticityInt J Neurosci2014124965265624392812
- Oreja-GuevaraCCasanovaBOrdásCMSilvánCVAsensioDMassanaMObservational Safety Study of THC: CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticityClin Exp Pharmacol201555184
- FlacheneckerPHenzeTZettlUKLong-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practiceEur Neurol2014721–29510224943098
- FlacheneckerPHenzeTZettlUKNabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice – results of a multicenter, non-interventional study (MOVE2) in patients with multiple sclerosis spasticityEur Neurol2014715–627127924525548
- FeinsteinAMultiple sclerosis and depressionMult Scler201117111276128122058085
- Royal College of PhysiciansNational Report: The National Audit of Services for People with Multiple Sclerosis2011 Available from: https://www.rcplondon.ac.uk/file/958/download?token=7NSA1NCxAccessed September 19, 2016
- FreidelMTiel-WilckKSchreiberHPrechtlAEssnerULangMDrug-resistant MS spasticity treatment with Sativex(®) add-on and driving abilityActa Neurol Scand2015131191625208898
- Sativex oromucosal spray package leafletGW Pharma Ltd2015 Available from: http://www.medicines.org.uk/emc/Accessed December 23, 2015